| ［1］ |
Byrne DJ, Deb S, Takano EA, et al. GATA3 expression in triple-negative breast cancers[J]. Histopathology, 2017, 71(1): 63-71.
|
| ［2］ |
Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2 500 epithelial and nonepithelial tumors[J]. Am J Surg Pathol, 2014, 38(1): 13-22.
|
| ［3］ |
Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+phenotype is more specific than CDX2 antibody[J]. Diagn Pathol, 2012, 7(1): 9.
|
| ［4］ |
Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer[J]. Lancet, 2025, 405(10485): 1182-1202.
|
| ［5］ |
Laurent E, Begueret H, Bonhomme B, et al. SOX10, GATA3, GCDFP15, androgen receptor, and mammaglobin for the differential diagnosis between triple-negative breast cancer and TTF1-negative lung adenocarcinoma[J]. Am J Surg Pathol, 2019, 43(3): 293-302.
|
| ［6］ |
Ai D, Yao J, Yang F, et al. TRPS1: A highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer[J]. Mod Pathol, 2021, 34(4): 710-719.
|
| ［7］ |
Lennartz M, Löhr N, Höflmayer D, et al. TRPS1 is a highly sensitive marker for breast cancer: A tissue microarray study evaluating more than 19 000 tumors from 152 different tumor entities[J]. Am J Surg Pathol, 2024, 48(6): 637-651.
|
| ［8］ |
Abdelwahed M, Yurtsever N, Savant D, et al. Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimens[J]. J Am Soc Cytopathol, 2022, 11(6): 345-351.
|
| ［9］ |
杨尹默, 田孝东. 胰腺癌多学科综合治疗协作组诊疗模式专家共识[J]. 中国实用外科杂志, 2017, 37(1): 35-36.
|